Company secures FDA 510k clearance for software upgrades designed to meet needs of patients outside of the ICU

TELFORD, Pa. - Dräger today announced that it has secured 510k clearance from the U.S. Food and Drug Administration (FDA) for an upgraded version of its Savina 300 ventilator that features enhanced capabilities for monitoring patients in ICU and non-ICU treatment areas.

Around the globe, Dräger Savina ventilators have logged more than 400 million hours of therapy time, setting standards for quality and reliability. Recognizing market demand for reliable, cost-effective and user-friendly ventilation technology for acute and long-term sub-acute care, Dräger developed this latest version of the Savina 300 with key capabilities designed specifically for these patient care settings.
The enhanced Dräger Savina 300 ventilator is approved for use in both adult and pediatric patients, accommodating 11mm pediatric circuits and tidal volumes as low as 20cc. New optional capabilities include mandatory minute ventilation (MMV) mode, airway pressure release ventilation (APRV) and end tidal CapnoPlus/CO2 integrated monitoring, all of which promote patient weaning efforts. As with all Drä[<00E4>][<00E4>]ger ventilators, the Savina 300 features the unique open breathing concept, which allows patients to breathe freely at any time during the cycle and at any pressure level.

With an intuitive user interface, larger graphics screen and numeric readings, the Drä[<00E4>][<00E4>]ger Savina 300 ventilator offers advanced therapy in a simple, easy to use device. The new internal turbine, which only requires replacement every eight years, contributes to its high performance and low cost of ownership.

"As the healthcare industry is challenged to deliver high quality care in a more cost-effective manner, there is a growing trend to expand the care of critically ill patients beyond the ICU and into sub-acute and long-term acute care facilities," says Ed Coombs, MA, RRT-NPS, ACCS, FAARC. "As healthcare evolves, we at Drä[<00E4>][<00E4>]ger are always delivering innovative technologies that meet the changing needs of clinicians and the patients they serve."

Dräger. Technology for Life®

Dräger is an international leader in the fields of medical and safety technology. Our products protect, support and save lives. Founded in 1889, in 2013 Dräger generated revenues of around EUR 2.37 billion. The Dräger Group is currently present in more than 190 countries and has about 13,500 employees worldwide. Please visit www.draeger.com for more information.

Contact Information:

Marion Varec
Dräger
www.draeger.com
215-660-2186

More HCB News